Grifols (NASDAQ:GRFS) Shares Gap Down - Here's Why

Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $7.40, but opened at $7.00. Grifols shares last traded at $7.15, with a volume of 362,744 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a report on Tuesday, October 29th.

Grifols Price Performance

The company has a fifty day moving average price of $7.66 and a 200-day moving average price of $8.19. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Institutional Trading of Grifols

A number of institutional investors have recently added to or reduced their stakes in GRFS. R Squared Ltd bought a new position in shares of Grifols during the 4th quarter valued at $28,000. GAMMA Investing LLC increased its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock worth $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC raised its holdings in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock valued at $48,000 after buying an additional 2,153 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Grifols during the 2nd quarter worth about $89,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.